All Stories

  1. The World Health Organisation's list of essential medicines and haemophilia treatment products

    Article • Haemophilia, October 2023, Wiley

    Albert Farrugia

  2. In response: Overestimation of fibrinogen concentration in cryoprecipitate by repeated freeze–thawing with long thawing period as used in the Clauss method

    Article • Transfusion, October 2023, Wiley

    Albert Farrugia

  3. The Evolution of the Safety of Plasma Products from Pathogen Transmission—A Continuing Narrative

    Article • Pathogens, February 2023, MDPI AG

    Albert Farrugia

  4. The best use of the French donors’ gift – Continuing an ethical tradition

    Article • Transfusion Clinique et Biologique, August 2022, Elsevier

    Albert Farrugia

  5. The legacy of haemophilia: Memories and reflections from three survivors

    Article • Haemophilia, May 2022, Wiley

    Albert Farrugia

  6. Therapeutic Solutions of Human Albumin – The Possible Effect of Process-Induced Molecular Alterations on Clinical Efficacy and Safety

    Article • Journal of Pharmaceutical Sciences, May 2022, Elsevier

    Albert Farrugia

  7. Fresh frozen plasma: Beyond coagulation factor content

    Article • Transfusion Medicine, January 2022, Wiley

    Albert Farrugia

  8. Albumin in plasma exchange – A rethink is required

    Article • Transfusion and Apheresis Science, October 2021, Elsevier

    Albert Farrugia

  9. Storage of cryoprecipitate: Role of blood storage

    Article • Transfusion, September 2021, Wiley

    Albert Farrugia

  10. The safety of plasma‐derived haemophilia factor concentrates – comments on “Deep viral metagenomics in patients with haemophilia receiving plasma‐derived coagulation factor concentrates” Nunes Valença I et al. (2021). Deep viral metagenomics in patient...

    Article • Haemophilia, August 2021, Wiley

    Albert Farrugia

  11. The discovery of cryoprecipitate as a modality for hemophilia A: Augmenting the allocation of credit

    Article • Transfusion, August 2021, Wiley

    Albert Farrugia

  12. Appropriately specifying the quality of plasma for fractionation

    Article • Vox Sanguinis, July 2021, Wiley

    Albert Farrugia

  13. Estimation of the latent therapeutic demand for immunoglobulin therapies in autoimmune neuropathies in the United States

    Article • Vox Sanguinis, June 2021, Wiley

    Albert Farrugia

  14. Is plasma donation ethics abused?

    Article • Transfusion Clinique et Biologique, February 2021, Elsevier

    Albert Farrugia

  15. The interphase between immunoglobulin, the plasma industry and the public health, managing a finite resource

    Article • Transfusion Clinique et Biologique, February 2021, Elsevier

    Albert Farrugia

  16. The art of the possible in approaching efficacy trials for COVID19 convalescent plasma

    Article • International Journal of Infectious Diseases, January 2021, Elsevier

    Albert Farrugia

  17. Intravenous Immunoglobulin Rich in Neutralising Antibodies to SARS-CoV-2 as a Passive Immunity Modality in Healthy Individuals at Risk of Infection With COVID-19: Study Protocol for an Open Label, Active Control Phase 1/2 Study.

    Article • December 2020, Research Square

    Albert Farrugia

  18. Urgent Need to Regulate Convalescent Plasma Differently from Thawed Plasma

    Article • Transfusion Medicine and Hemotherapy, December 2020, Karger Publishers

    Daniele Focosi, Albert Farrugia

  19. ABO‐incompatible convalescent plasma transfusion: Yes, you can

    Article • Transfusion Medicine, November 2020, Wiley

    Albert Farrugia

  20. Supporting Garraud – and protecting transfusion

    Article • Transfusion Clinique et Biologique, August 2020, Elsevier

    Albert Farrugia

  21. Plasma from donors convalescent from SARS-CoV-2 infection–A matter of priorities

    Article • Transfusion Clinique et Biologique, August 2020, Elsevier

    Albert Farrugia

  22. Convalescent plasma – this is no time for competition

    Article • Transfusion, June 2020, Wiley

    Albert Farrugia

  23. Latent Therapeutic Demand of Immunoglobulin therapies in neuropathies in the United States

    Article • June 2020, Cold Spring Harbor Laboratory Press

    Albert Farrugia

  24. The impact of the SARS-CoV-2 outbreak on the safety and availability of blood transfusions in Italy

    Article • Vox Sanguinis, April 2020, Wiley

    Albert Farrugia

  25. Concerns regarding immunoglobulins

    Article • Transfusion and Apheresis Science, April 2020, Elsevier

    Albert Farrugia

  26. Pharmacokinetics of a new human plasma‐derived double virus inactivated and nanofiltered factor IX concentrate in previously treated severe or moderately severe haemophilia B patients

    Article • Haemophilia, September 2019, Wiley

    Albert Farrugia

  27. Pharmacokinetic and safety considerations when switching from standard to extended half-life clotting factor concentrates in hemophilia

    Article • Expert Review of Hematology, July 2019, Taylor & Francis

    Massimo Morfini, Albert Farrugia

  28. Comparing objective and self‐reported measures of adherence in haemophilia

    Article • Haemophilia, July 2019, Wiley

    Albert Farrugia

  29. Herd immunity and primary immune deficiencies

    Article • Vaccine, July 2019, Elsevier

    Albert Farrugia

  30. Health-Related Quality of Life in Patients with CVID Under Different Schedules of Immunoglobulin Administration: Prospective Multicenter Study

    Article • Journal of Clinical Immunology, January 2019, Springer Science + Business Media

    Albert Farrugia

  31. Comparative analysis of marketed factor VIII products: comment

    Article • Journal of Thrombosis and Haemostasis, December 2018, Wiley

    Albert Farrugia

  32. The burden of common variable immunodeficiency disorders: a retrospective analysis of the European Society for Immunodeficiency (ESID) registry data

    Article • Orphanet Journal of Rare Diseases, November 2018, Springer Science + Business Media

    Albert Farrugia

  33. Improving access to haemophilia therapies-Beyond humanitarian aid

    Article • Haemophilia, October 2018, Wiley

    Albert Farrugia

  34. Perspectives on haemophilia access in Brazil?

    Article • Haemophilia, June 2018, Wiley

    Dr Patrick A Wachholz, Sergio Souza, Albert Farrugia

  35. The multiple benefits of sport in haemophilia

    Article • Haemophilia, May 2018, Wiley

    Albert Farrugia

  36. Factor VIII manufactured from plasma—the ups and downs, and the up again: a personal journey—part 1: history of the development of plasma-derived factor VIII therapies

    Article • Annals of Blood, February 2018, AME Publishing Company

    Albert Farrugia

  37. Factor VIII manufactured from plasma—the ups and downs, and the up again: a personal journey—part 2: aspects of factor VIII manufacture from plasma

    Article • Annals of Blood, February 2018, AME Publishing Company

    Albert Farrugia

  38. Obituary: Duncan Stephen Pepper, 1942-2017

    Article • Transfusion Medicine, October 2017, Wiley

    Albert Farrugia

  39. Concerns regarding clinical trials in haemophilia-Augmenting Iorio's “Research and policy implications of a recently published controlled study in previously untreated haemophilia patients at high risk of inhibitor development” Haemophilia (2017), 1-3 htt

    Article • Haemophilia, July 2017, Wiley

    Albert Farrugia

  40. Time to review the way we estimate access to haemophilia concentrates worldwide

    Article • Haemophilia, May 2017, Wiley

    Albert Farrugia

  41. The dynamics of contract plasma fractionation

    Article • Biologicals, March 2017, Elsevier

    Albert Farrugia

  42. Usual and unusual mutations in a cohort of Belgian patients with hemophilia B

    Article • Thrombosis Research, January 2017, Elsevier

    Albert Farrugia

  43. Innovation in Hemophilia Therapies — “And Miles to Go, before [We] Sleep”

    Article • Seminars in Thrombosis and Hemostasis, December 2016, Thieme Publishing Group

    Albert Farrugia

  44. Are we optimising outcomes in Australia’s framework for the supply of plasma-derived medicines?

    Article • The Medical Journal of Australia, October 2016, Australasian Medical Publishing Co. Pty Ltd. (AMPCo)

    Albert Farrugia

  45. Safety Issues of Plasma-Derived Products for Treatment of Inherited Bleeding Disorders

    Article • Seminars in Thrombosis and Hemostasis, April 2016, Thieme Publishing Group

    Albert Farrugia

  46. Where now for transfusion: the evolution of a paradigm and its logical progression

    Article • Transfusion, April 2016, Wiley

    Albert Farrugia

  47. Editorial: Immunoglobulin Therapy in the 21st Century – the Dark Side of the Moon

    Article • Frontiers in Immunology, August 2015, Frontiers

    Albert Farrugia

  48. Ethical issues in clinical trials

    Article • Journal of Blood Medicine, June 2015, Dove Medical Press

    Steffen Schlenkrich , Uwe Schlenkrich, Albert Farrugia

  49. Assessing options for treating haemophilia with inhibitors

    Article • Haemophilia, April 2015, Wiley

    Albert Farrugia

  50. Errors and Omissions: Donor Compensation Policies and Richard Titmuss

    Article • HEC Forum, February 2015, Springer Science + Business Media

    Albert Farrugia

  51. Reflections on the emergence of chikungunya virus in the United States: time to revisit a successful paradigm for the safety of blood-derived therapies

    Article • Transfusion, January 2015, Wiley

    Albert Farrugia

  52. Estimation of the latent therapeutic demand for albumin in the USA: a focus on three indications

    Article • Critical Care, January 2015, Springer Science + Business Media

    Albert Farrugia

  53. Use of albumin in spontaneous bacterial peritonitis is cost-effective

    Article • Critical Care, January 2015, Springer Science + Business Media

    Albert Farrugia

  54. Manufacture of Immunoglobulin Products for Patients with Primary Antibody Deficiencies – The Effect of Processing Conditions on Product Safety and Efficacy

    Article • Frontiers in Immunology, December 2014, Frontiers

    Albert Farrugia

  55. Hemolysis in patients with antibody deficiencies on immunoglobulin replacement treatment

    Article • Transfusion, December 2014, Wiley

    Albert Farrugia

  56. The Ethics of Paid Plasma Donation: A Plea for Patient Centeredness

    Article • HEC Forum, September 2014, Springer Science + Business Media

    Albert Farrugia

  57. Choice of Fluids in Severe Septic Patients - A Cost-effectiveness Analysis Informed by Recent Clinical Trials

    Article • Reviews on Recent Clinical Trials, May 2014, Bentham Science Publishers

    Professor Greg Martin, Albert Farrugia

  58. Joint WFH-ISTH session: issues in clinical trial design

    Article • Haemophilia, April 2014, Wiley

    Albert Farrugia

  59. Products Used to Treat Hemophilia: Regulation

    Article • April 2014, Wiley

    Albert Farrugia

  60. Hemophilia treatment and the AIDS tragedy: closing the circle

    Article • Transfusion, April 2014, Wiley

    Albert Farrugia

  61. Toward a patient-based paradigm for blood transfusion

    Article • Journal of Blood Medicine, January 2014, Taylor & Francis

    Albert Farrugia

  62. Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare Diseases

    Article • Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation, January 2014, COPD Foundation

    Albert Farrugia

  63. Modeling Primary Immunodeficiency Disease Epidemiology and Its Treatment to Estimate Latent Therapeutic Demand for Immunoglobulin

    Article • Journal of Clinical Immunology, December 2013, Springer Science + Business Media

    Albert Farrugia

  64. Relative Survival Benefit and Morbidity with Fluids in Severe Sepsis - A Network Meta-Analysis of Alternative Therapies

    Article • Current Drug Safety, October 2013, Bentham Science Publishers

    Professor Greg Martin, Albert Farrugia

  65. Treatment for life for severe haemophilia A- A cost-utility model for prophylaxis vs. on-demand treatment

    Article • Haemophilia, March 2013, Wiley

    Albert Farrugia

  66. Economic considerations on transfusion medicine and patient blood management

    Article • Best Practice & Research Clinical Anaesthesiology, March 2013, Elsevier

    Mr Shannon L Farmer, Albert Farrugia

  67. External Financial Aid to Blood Transfusion Services in Sub-Saharan Africa: A Need for Reflection

    Article • PLoS Medicine, September 2012, PLOS

    DR MRS Shirley Owusu-Ofori, Albert Farrugia

  68. The Boldt Affair

    Article • Anesthesia & Analgesia, July 2012, Wolters Kluwer Health

    Albert Farrugia

  69. Assessing causality in the transmission of viruses by blood products

    Article • Transfusion, July 2012, Wiley

    Albert Farrugia

  70. Albumin from rice: Why and wherefore?

    Article • Proceedings of the National Academy of Sciences, March 2012, Proceedings of the National Academy of Sciences

    Albert Farrugia

  71. Health technology assessment and haemophilia

    Article • Haemophilia, February 2012, Wiley

    Albert Farrugia

  72. Letter to the Editor - Response to ‘How expanding voluntary non-remunerated blood donations would benefit patients, donors and healthcare systems?’- F. Rossi, R. Perry, J. de Wit,T. Evers & G. Folléa, Vox Sanguinis DOI: 10.1111/j.1423-0410.2011.01495.x

    Article • Vox Sanguinis, October 2011, Wiley

    Albert Farrugia

  73. Conditions for plasma processing

    Article • Transfusion, August 2011, Wiley

    Albert Farrugia

  74. Response to Laub et al., ‘Specific protein content of pools of plasma for fractionation from different sources: impact of frequency of donations’, Vox Sanguinis (2010) 99, 220-231

    Article • Vox Sanguinis, April 2011, Wiley

    Albert Farrugia

  75. Safety of Plasma Volume Expanders

    Article • The Journal of Clinical Pharmacology, March 2011, Wiley

    Albert Farrugia

  76. A study of reported factor IX use around the world

    Article • Haemophilia, February 2011, Wiley

    Albert Farrugia

  77. HIV safety in sub-Saharan Africa

    Article • Vox Sanguinis, October 2010, Wiley

    Albert Farrugia, Mr Francis Sarkodie

  78. Response to Volkow P et al. – Cross-border paid plasma donation among injection drug users in two Mexico–U.S. border cities – International Journal of Drug Policy 20 (2009) 409–412

    Article • International Journal of Drug Policy, September 2010, Elsevier

    Albert Farrugia

  79. Falsification or paradigm shift? Toward a revision of the common sense of transfusion

    Article • Transfusion, August 2010, Wiley

    Albert Farrugia

  80. Products used to Treat Hemophilia: Regulation

    Article • August 2010, Wiley

    Albert Farrugia

  81. Payment, compensation and replacement - the ethics and motivation of blood and plasma donation

    Article • Vox Sanguinis, June 2010, Wiley

    Albert Farrugia

  82. Albumin Usage in Clinical Medicine: Tradition or Therapeutic?

    Article • Transfusion Medicine Reviews, January 2010, Elsevier

    Albert Farrugia

  83. Concerning Chapter 5 – Human Albumin; in Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives, 4th ed. Transfus Med Hemother 2009;36(6):399–407

    Article • Transfusion Medicine and Hemotherapy, January 2010, Karger Publishers

    Albert Farrugia

  84. A study of reported factor VIII use around the world

    Article • Haemophilia, December 2009, Wiley

    Albert Farrugia

  85. Globalisation and blood safety

    Article • Blood Reviews, May 2009, Elsevier

    Albert Farrugia

  86. Remuneration of blood donors: let us compare apples with apples

    Article • Vox Sanguinis, May 2009, Wiley

    Albert Farrugia

  87. Plasma fractionation issues

    Article • Biologicals, April 2009, Elsevier

    Albert Farrugia

  88. Stem cell and cellular therapy developments

    Article • Biologicals, April 2009, Elsevier

    Albert Farrugia

  89. Trialing plasma protein therapies for rare disorders: Thinking outside the box

    Article • Pharmaceuticals Policy and Law, January 2009, IOS Press

    Albert Farrugia

  90. Comparison of the risk of viral infection between the living and nonliving musculoskeletal tissue donors in Australia

    Article • Transplant International, October 2008, Wiley

    Albert Farrugia, Doctor Clive R Seed

  91. Trends in Prevalence of Viral Infections in Australian Musculoskeletal Tissue Donors and Projections of Incidence and Residual Risk, 1993–2004

    Article • Transplantation, September 2008, Wolters Kluwer Health

    Albert Farrugia, Doctor Clive R Seed

  92. Platelet size analysis in the quality assurance of platelet concentrates for transfusion

    Article • International Journal of Laboratory Hematology, June 2008, Wiley

    Albert Farrugia

  93. Reply

    Article • Transfusion, December 2007, Wiley

    Albert Farrugia, Doctor Clive R Seed

  94. The Risk of HIV, HBV, HCV and HTLV Infection Among Musculoskeletal Tissue Donors in Australia

    Article • American Journal of Transplantation, December 2007, Wiley

    Albert Farrugia, Doctor Clive R Seed

  95. Theoretically estimated risk of severe acute respiratory syndrome transmission through blood transfusion during an epidemic in Shenzhen, Guangdong, China in 2003

    Article • Transfusion and Apheresis Science, December 2007, Elsevier

    Albert Farrugia

  96. Residual risk of transfusion-transmitted viral infections in Shenzhen, China, 2001 through 2004

    Article • Transfusion, March 2007, Wiley

    Albert Farrugia, Doctor Clive R Seed

  97. Global Forum of the World Federation of Hemophilia, September 26–27, 2005, Montreal, Quebec, Canada

    Article • Transfusion and Apheresis Science, October 2006, Elsevier

    Albert Farrugia

  98. CHALLENGES IN THE EVALUATION OF SAFETY AND EFFICACY OF HUMAN TISSUE AND CELL BASED PRODUCTS

    Article • ANZ Journal of Surgery, September 2006, Wiley

    Albert Farrugia

  99. When do tissues and cells become products? – Regulatory oversight of emerging biological therapies

    Article • Cell and Tissue Banking, June 2006, Springer Science + Business Media

    Albert Farrugia

  100. Plasma protein therapies: current and future perspectives

    Article • Best Practice & Research Clinical Haematology, March 2006, Elsevier

    Albert Farrugia

  101. Assessing Efficacy and Therapeutic Claims in Emerging Indications for Recombinant Factor VIIa: Regulatory Perspectives

    Article • Seminars in Hematology, January 2006, Elsevier

    Albert Farrugia

  102. Variant Creutzfeldt-Jakob disease transmission by plasma products: assessing and communicating risk in an era of scientific uncertainty

    Article • Vox Sanguinis, November 2005, Wiley

    Albert Farrugia

  103. Choice of replacement therapy for hemophilia-cryoprecipitate issues: a rebuttal

    Article • Journal of Thrombosis and Haemostasis, June 2004, Wiley

    Albert Farrugia

  104. The mantra of blood safety: time for a new tune?

    Article • Vox Sanguinis, January 2004, Wiley

    Albert Farrugia

  105. The Cambridge Healthtech Institute’s 9th Annual Conference on Blood Safety

    Article • Expert Opinion on Drug Safety, July 2003, Informa Healthcare

    Albert Farrugia

  106. Risk of parvovirus infection by immunoglobulin

    Article • British Journal of Haematology, June 2003, Wiley

    Albert Farrugia

  107. Modulation of fibrinogen content in cryoprecipitate by temperature manipulation during plasma processing

    Article • Transfusion, February 2003, Wiley

    Albert Farrugia

  108. The Cambridge Healthtech Institute?s 9th Annual Conference on Blood Safety

    Article • Expert Opinion on Drug Safety, January 2003, Informa Healthcare

    Albert Farrugia

  109. The regulatory pendulum in transfusion medicine

    Article • Transfusion Medicine Reviews, October 2002, Elsevier

    Albert Farrugia

  110. Evolving perspectives in product safety for haemophilia

    Article • Haemophilia, May 2002, Wiley

    Albert Farrugia

  111. Haemophilia 2002: emerging risks of treatment

    Article • Haemophilia, May 2002, Wiley

    Albert Farrugia

  112. Risk of variant Creuzfeldt-Jakob disease from factor concentrates: current perspectives

    Article • Haemophilia, May 2002, Wiley

    Albert Farrugia

  113. Laboratory practice and studies of bovine spongiform encephalopathy

    Article • The Lancet, March 2002, Elsevier

    Albert Farrugia

  114. Intravenous immunoglobulin: regulatory perspectives on use and supply

    Article • Transfusion Medicine, April 2001, Wiley

    Albert Farrugia

  115. Flow–Cytometric Method for the Quantitation of the Fc Function of Intravenous Immunoglobulin Preparations

    Article • Vox Sanguinis, January 2000, Karger Publishers

    Albert Farrugia

  116. Biological Activity of von Willebrand factor during the manufacture of therapeutic factor VIII concentrates as determined by the collagen-binding assay

    Article • Biologicals, June 1998, Elsevier

    Albert Farrugia

  117. Measurement of Anticomplementary Activity in Therapeutic Intravenous Immunoglobulin Preparations

    Article • Biologicals, March 1997, Elsevier

    Albert Farrugia

  118. Hepatitis C virus transmission by intravenous immunoglobulin

    Article • The Lancet, August 1995, Elsevier

    Albert Farrugia

  119. Relative Efficiency of Leucocyte Removal Procedures for the Production of Leucocyte-Poor Red Cell Concentrates Assessed by Flow Cytometry

    Article • Vox Sanguinis, April 1994, Wiley

    Albert Farrugia

  120. In vitro properties of additive suspended red cells collected into a dextrose-free anticoagulant

    Article • Transfusion Science, March 1994, Elsevier

    Albert Farrugia

  121. Platelet Concentrates for Transfusion—Metabolic and Storage Aspects

    Article • Platelets, January 1994, Taylor & Francis

    Albert Farrugia

  122. Components prepared from blood collected into dextrose-free anticoagulant. In vitro properties of platelets suspended in plasma and in dextrose-free synthetic medium

    Article • Transfusion Science, October 1993, Elsevier

    Albert Farrugia

  123. Storage of platelet concentrates harvested from blood collected into dextrose-free preservative without agitation

    Article • Transfusion Medicine, September 1993, Wiley

    Albert Farrugia

  124. Cryopreservation of red blood cells: effect of freezing on red cell quality and residual lymphocyte immunogenicity.

    Article • Journal of Clinical Pathology, August 1993, BMJ

    Albert Farrugia

  125. Stablization of von Willebrand factor in banked blood by leucocyte depletion

    Article • Transfusion Medicine, March 1993, Wiley

    Albert Farrugia

  126. Factor VIII/von willebrand factor levels in plasma frozen to - 30 ° C in air or halogenated hydrocarbons

    Article • Thrombosis Research, October 1992, Elsevier

    Albert Farrugia

  127. Red Cell and Platelet Concentrates from Blood Collected into Half-Strength Citrate Anticoagulant: Improved Maintenance of Red Cell 2,3-Diphosphoglycerate in Half-Citrate Red Cells

    Article • Vox Sanguinis, August 1992, Wiley

    Albert Farrugia

  128. Von Willebrand factor characterization of a severe dry-heat treated factor VIII concentrate, AHF (high purity)

    Article • Thrombosis Research, February 1992, Elsevier

    Albert Farrugia

  129. Improved in-vitro quality of platelet concentrates stored in a dextrose-free synthetic medium

    Article • Transfusion Medicine, March 1991, Wiley

    Albert Farrugia

  130. Viral safety of coagulation factor concentrates

    Article • Transfusion Science, January 1991, Elsevier

    Albert Farrugia

  131. Microtitre plate measurement of platelet response to hypotonic stress.

    Article • Journal of Clinical Pathology, December 1989, BMJ

    Albert Farrugia

  132. Effects of Plasma Collection Systems and Processing Parameters on the Quality of Factor IX Concentrate

    Article • Vox Sanguinis, July 1989, Wiley

    Albert Farrugia

  133. A microtitre plate test for assesment of in-vitro thrombogenicity in factor IX concentrates using a chromogenic substrate

    Article • Thrombosis Research, January 1989, Elsevier

    Albert Farrugia

  134. Studies on the Procurement of Blood Coagulation Factor VIII in vitro Studies on Blood Components Prepared in Half-Strength Citrate Anticoagulant

    Article • Vox Sanguinis, May 1987, Wiley

    Albert Farrugia

  135. Donation Procedure, Fibrinopeptide A, and Factor VIII

    Article • Vox Sanguinis, January 1984, Wiley

    Albert Farrugia

  136. Products Used to Treat Hemophilia: Regulation

    Article • Wiley

    Albert Farrugia